|Last Price$4.25||Day Change (%)-4.49%|
|Open Price$4.44||Day Change ($)-0.20|
|Day Range4.24–4.48||52-Week Range3.96–13.38|
As of Thu 07/24/2014 04:53 PM EST | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.